NUMAFERM
Key Facts
| Invested since | 2017 |
| Based in | North Rhine-Westphalia |
About the company
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. They serve customers from pharma, biotech, agriculture, and cosmetics offering peptides and proteins at highest qualities, within weeks, in a sustainable way. In this context partnership deals with global CDMO PolyPeptide and the world’s leading animal health company Zoetis were closed.
Founded in 2017 as a spin-out of Düsseldorf University, Numaferm has grown to over 20 staff.
Do you want to
know more about this company?
NUMAFERM in the news
Zum Artikel
Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides
More startups from Life Sciences
Exit
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
To the complete profileof Amal Therapeutics
Exit
Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for …
To the complete profileof Amedrix
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …
To the complete profileof WMT
Exit
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
To the complete profileof Fiagon
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx
Exit
Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall …
To the complete profileof Belyntic
Exit
GME German Medical Engineering develops and markets a new generation of laser and lightsystems (small, light weight, modular) for the use in cosmetic and medical dermatology.
To the complete profileof GME
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
To the complete profileof ChromoTek
Exit
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …
To the complete profileof KSK Diagnostics
Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to …
To the complete profileof Altavo
ActiTrexx GmbH is a spin-off from the University Medical Center Mainz and was founded in 2020. The company develops ATreg, a cell therapy based on activated regulatory T cells that …
To the complete profileof ActiTrexx